Saturday, February 1, 2020

Non-oncology drugs helps kill cancer cells

Research at Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute shows that many non-oncology drugs, including the drugs for diabetes, inflammation, alcoholism -- and even for treating arthritis in dogs kill cancer cells in lab. The researchers analyzed thousands of already developed drug compounds and found nearly 50 that have previously unrecognized anti-cancer activity. The surprising findings, which also revealed novel drug mechanisms and targets, suggest a possible way to accelerate the development of new cancer drugs or repurpose existing drugs to treat cancer.

The researchers tested all the compounds in the Drug Repurposing Hub on 578 human cancer cell lines from the Broad's Cancer Cell Line Encyclopedia (CCLE). Using a molecular barcoding method known as PRISM, which was developed in the Golub lab, the researchers tagged each cell line with a DNA barcode, allowing them to pool several cell lines together in each dish and more quickly conduct a larger experiment. The team then exposed each pool of barcoded cells to a single compound from the repurposing library and measured the survival rate of the cancer cells.

They found nearly 50 non-cancer drugs -- including those initially developed to lower cholesterol or reduce inflammation -- that killed some cancer cells while leaving others alone.

Some of the compounds killed cancer cells in unexpected ways. "Most existing cancer drugs work by blocking proteins, but we're finding that compounds can act through other mechanisms," said Corsello. Some of the four-dozen drugs he and his colleagues identified appear to act not by inhibiting a protein but by activating a protein or stabilizing a protein-protein interaction. For example, the team found that nearly a dozen non-oncology drugs killed cancer cells that express a protein called PDE3A by stabilizing the interaction between PDE3A and another protein called SLFN12 -- a previously unknown mechanism for some of these drugs.

These unexpected drug mechanisms were easier to find using the study's cell-based approach, which measures cell survival, than through traditional non-cell-based high-throughput screening methods, Corsello said.

Most of the non-oncology drugs that killed cancer cells in the study did so by interacting with a previously unrecognized molecular target. For example, the anti-inflammatory drug tepoxalin, originally developed for use in people but approved for treating osteoarthritis in dogs, killed cancer cells by hitting an unknown target in cells that overexpress the protein MDR1, which commonly drives resistance to chemotherapy drugs.

The researchers were also able to predict whether certain drugs could kill each cell line by looking at the cell line's genomic features, such as mutations and methylation levels, which were included in the CCLE database. This suggests that these features could one day be used as biomarkers to identify patients who will most likely benefit from certain drugs. For example, the alcohol dependence drug disulfiram (Antabuse) killed cell lines carrying mutations that cause depletion of metallothionein proteins. Compounds containing vanadium, originally developed to treat diabetes, killed cancer cells that expressed the sulfate transporter SLC26A2.

"The genomic features gave us some initial hypotheses about how the drugs could be acting, which we can then take back to study in the lab," said Corsello. "Our understanding of how these drugs kill cancer cells gives us a starting point for developing new therapies."

The researchers hope to study the repurposing library compounds in more cancer cell lines and to grow the hub to include even more compounds that have been tested in humans. The team will also continue to analyze the trove of data from this study, which have been shared openly ( with the scientific community, to better understand what's driving the compounds' selective activity.

To explore more interesting trends in cancer research, do join us at Paris, France, this July 1-2, 2020. For more info, PS: Cancer Research 2020 | Brochure

Saturday, October 5, 2019

Saturday, September 28, 2019

Cancer Summit 2019

Study shows that combination of cediranib and olaparib proves effective and safe for women with heavily pretreated, platinum-resistant ovarian cancer. To explore more oncology, PS:

Saturday, September 7, 2019

Breakthrough therapy designation to capmatinib- Lung Cancer

The FDA granted breakthrough therapy designation to capmatinib for first-line treatment of metastatic MET exon 14 skipping-mutated non-small cell lung cancer.
MET mutations — identified in approximately 4% of patients with NSCLC — are associated with poor prognosis. The mutations, typically seen among older patients, can limit treatment options.
No targeted therapies are approved to treat MET exon 14 skipping-mutated NSCLC, an aggressive subtype of the disease.
Prior studies have shown capmatinib (INC280, Novartis) — an investigational, oral MET inhibitor — to be highly selective and potent in this setting, according to a Novartis-issued press release. The FDA previously granted breakthrough therapy designation to the agent for treatment of patients with this type of NSCLC who received prior platinum-based chemotherapy.
“We look forward to working with the FDA and global health authorities to bring capmatinib to patients who currently have no available targeted therapy options,” John Tsai, MD, head of global drug development and chief medical officer of Novartis, said in the release.

Tuesday, August 27, 2019

Recent Trends in Oncology

Study shows that de-intensified chemoradiotherapy regimen shows favorable clinical outcomes among for HPV-associated oropharyngeal squamous cell carcinoma. Learn more about oncology at: